Experiences with continuous infusion of recombinant activated factor VII

Blood Coagulation and Fibrinolysis

Volumn 9, Issue SUPPL. 1, 1998, Pages

  Schulman, S ^a,b   D'Oiron, R ^c   Martinowitz, U ^b   Pasi, J ^d   Briquel, M E ^e   Mauser Bunschoten, E ^f   Morfini, M ^g   Ritchie, B ^h   Goudemand, J ⁱ   Lloyd, J ^j   McPherson, J ^k   Negrier C ^l   Peerlinck, K ^m   Petrini, P ^a   Tusell, J ⁿ  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SHEBA MEDICAL CENTER   (Israel)

^c BICÊTRE HOSPITAL   (France)

^d ROYAL FREE HOSPITAL   (United Kingdom)

^e UNIVERSITY HOSPITAL OF NANCY   (France)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g CAREGGI UNIVERSITY HOSPITAL   (Italy)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ LILLE UNIVERSITY HOSPITAL   (France)

^j INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^k UNIVERSITY OF NEWCASTLE   (Australia)

^l EDOUARD HERRIOT HOSPITAL   (France)

^m UNIVERSITY OF LEUVEN   (Belgium)

ⁿ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

more..

Author keywords

Continuous infusion; Factor VIIa; Haemophilia; Haemorrhage; Inhibitors; Surgery

Indexed keywords

ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BLEEDING; BLOOD CLOTTING; CLINICAL ARTICLE; CONFERENCE PAPER; CONTINUOUS INFUSION; DOSE RESPONSE; HEMOPHILIA; HUMAN; PATIENT MONITORING; PRIORITY JOURNAL; QUESTIONNAIRE; THROMBOPHLEBITIS;

EID: 0031759475     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (7)

1. Hedner U, Glazer S, Pingel K, Alberts KA, Blombäck M, Schulman S, Johnsson H. Successful use of recombinant factor Vila in patient with severe haemophilia A during synovectomy [letter]. Lancet 1988; ii:1193.
2. Martinowitz U, Schulman S. Continuous infusion of coagulation products. Int J Pediatr Hematol Oncol 1994; 1:471-478.
3. Schulman S, Bech Jensen M, Varon D, Keller N, Gitel S, Horoszowski H, et al. Feasibility of using recombinant factor Vila in continuous infusion. Thromb Haemost 1996; 75:432-436.
4. Hedner U. Experiences with recombinant factor VIIa in haemophiliacs. In: Biotechnology of plasma proteins. Albertini A, Lenfant CL, Mannucci PM, Sixma JJ (editors). Basel: Karger; Curr Studies Hematol Blood TRansf 1991; 58:63-68.
5. Ingerslev J, Sneppen O, Knudsen L, Sindet-Pedersen S. Effect of recombinant factor VIIa (rFVIIa) in surgical procedures in haemophilia A patients with inhibitors and congenital factor VII deficiency. In: 24 Hämophilie-Symposium, Hamburg 1994. Scharrer I, Schramm W (editors). Berlin: Springer-Verlag; 1994. pp. 122-125.
6. Stieltjes N, Ounnoughene N, Vassilieff D, Sultan Y. Failure of recombinant factor VIIa to control surgical bleeding in a severe hemophilia A patient with an inhibitor and possible DIC [abstract PS-202]. Thromb Haemost 1997; suppl 50.50.
7. Lindley CM, Sawyer WT, Macik BG, Lusher J, Harrison JF, Baird-Cox K, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994;55:638-648.